摘要
抗血栓形成剂特别是抗血小板药物,例如阿司匹林和氯吡格雷的使用已经在纵多患者降低心血管不良反应中起作用。然而,尽管有确定疗效,这些药物的使用仍然没有达到最理想的程度。对于这些药物治疗,存在高度的个体差异,即使维持在一个合适的治疗方案,患者还是发生了闭塞性血栓栓塞。这就引出了抗血栓障碍和抗血栓不良反应的概念,这些都引起了临床医生和其他医疗保健推昌者越来越多的关注。进一步考虑这个问题,已有报道指出使用非甾体抗炎药例如布洛芬和萘普生会增加心血管疾病发病风险,揭示了非甾体抗炎药对心肌梗死和中风也有附加的或不可预料的作用。有时,要平衡所有的药物其潜在的风险和益处似乎与其说是科学不如说是艺术。然而,考虑到它广泛的使用和严重的心血管影响,进一步研究的重心将集中于了解抗血栓和非甾体抗炎药治疗的影响因素。心血管遗传药理学的主要目的是在心血管疾病中发现能被用来做前瞻性筛选和药效和药物不良反应个体预测的遗传生物标记物。
关键词: 抗血小板,抗血栓,阿司匹林,环氧化酶-1和环氧化酶-2,非甾体抗炎药,遗传药理学。
Current Molecular Medicine
Title:Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Volume: 14 Issue: 7
Author(s): J. Stitham, P. Vanichakarn, L. Ying and J. Hwa
Affiliation:
关键词: 抗血小板,抗血栓,阿司匹林,环氧化酶-1和环氧化酶-2,非甾体抗炎药,遗传药理学。
摘要: The use of antithrombotic agents, particularly antiplatelet drugs like aspirin and clopidogrel, has been instrumental in decreasing the risk for adverse cardiovascular events across a wide range of patients. However, despite the established benefits, the use of these medications remains suboptimal. There is a high degree of inter-individual variation in response to these treatments, whereby patients experience occlusive thromboembolic events, in spite of maintaining an appropriate treatment regimen. This has lead to the notion of antithrombotic “resistance” or “poor responders”, which has been a growing concern amongst clinicians and other healthcare providers. Compounding this matter even further, reports of increased cardiovascular risk associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, have revealed additional and unforeseen contributors to myocardial infarction and stroke. With all medications, striking a balance between the potential risks and benefits seems more art than science at times. However, given their widespread use and critical cardiovascular implications, further emphasis has been placed on understanding factors influencing antithrombotic and NSAID therapies. A major aim in cardiovascular pharmacogenetics is the discovery of genetic biomarkers that will allow for prospective screening and individualized prediction of drug efficacy and adverse reactions for these medications (both alone and together) within the context of cardiovascular disease.
Export Options
About this article
Cite this article as:
Stitham J., Vanichakarn P., Ying L. and Hwa J., Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811121109
DOI https://dx.doi.org/10.2174/1566524014666140811121109 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Current Hypertension Reviews Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Obesity in the Patient with Lung Disease
Current Respiratory Medicine Reviews Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Anti-Cancer Agents in Medicinal Chemistry Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus
Current Diabetes Reviews Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Identifying Structural Features Related to the Biological Activity of a Series of AT1 Antagonists from Fragment-based Drug Design
Protein & Peptide Letters The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Lipid Carriers for Gene Therapy
Current Drug Delivery Patent Annotations
Recent Patents on Anti-Infective Drug Discovery